GRI Bio Inc. (GRI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GRI Bio Inc. (GRI) has a cash flow conversion efficiency ratio of -0.349x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.69 Million) by net assets ($10.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is GRI Bio Inc.'s balance sheet to measure how much of total assets are equity-financed.
GRI Bio Inc. - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how GRI Bio Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check GRI Bio Inc. cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
GRI Bio Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GRI Bio Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Awilco Drilling PLC
OL:AWDR
|
0.616x |
|
ZW Data Action Technologies Inc
NASDAQ:CNET
|
-0.067x |
|
Australia United Mining Ltd
AU:AYM
|
-0.054x |
|
Comanche International Public Company Limited
BK:COMAN
|
-0.002x |
|
Farmmi Inc
NASDAQ:FAMI
|
0.306x |
|
Zoomcar Holdings Inc.
NASDAQ:ZCAR
|
0.131x |
|
Prima Cakrawala Abadi PT
JK:PCAR
|
0.183x |
|
Brooks Macdonald Group
LSE:BRK
|
0.107x |
Annual Cash Flow Conversion Efficiency for GRI Bio Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of GRI Bio Inc. from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see GRI Bio Inc. (GRI) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.01 Million | $-10.19 Million | -1.695x | +20.61% |
| 2024-12-31 | $4.03 Million | $-8.61 Million | -2.136x | +93.85% |
| 2023-12-31 | $259.00K | $-8.99 Million | -34.710x | -5298.57% |
| 2022-12-31 | $-1.62 Million | $-1.08 Million | 0.668x | +272.39% |
| 2021-12-31 | $-4.72 Million | $-847.00K | 0.179x | -92.97% |
| 2020-12-31 | $-1.45 Million | $-3.71 Million | 2.549x | +384.06% |
| 2019-12-31 | $3.21 Million | $-2.88 Million | -0.897x | +94.21% |
| 2018-12-31 | $152.94K | $-2.37 Million | -15.503x | -- |
About GRI Bio Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung … Read more